BELFAST, Northern Ireland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and ...
BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and ...
CV6 Therapeutics (NI) Ltd. has secured US$9.2 million to progress its lead oncology asset CV6-168 into a first-in-human phase Ia trial and perform further scientific development work. CV6-168 is a ...
CV6 Therapeutics is developing next-generation cancer treatment, and it is looking backwards to make the future better. Emily McDaid reports. CV6 Therapeutics doesn’t replace traditional chemotherapy; ...
CV6 Therapeutics will conduct further research with Queen’s University Belfast while clinical trials are going on. Belfast-based CV6 Therapeutics has raised £8m to invest in clinical trials and ...
CV6 Therapeutics Ltd. raised $9.2 million in grant and equity funding to move a first-in-class inhibitor of deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase) into a phase Ia trial in cancer.
Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback